90.75
+1.65(+1.85%)
Currency In HKD
Address
168 Dongping Street
Suzhou, 215123
China
Phone
86 512 6956 6088
Website
Sector
Healthcare
Industry
Biotechnology
Employees
5659
First IPO Date
October 31, 2018
| Name | Title | Pay | Year Born |
| De-Chao Yu | Co-Founder, Chairman & Chief Executive Officer | 44.76M | 1964 |
| Qian Zhang | Chief People Officer, GM & Executive Director | 3.08M | 1987 |
| Hao Xi Ede | Executive Director & Fund Managing Partner | 7.89M | 1959 |
| Kaisong Zhou | Chief Operating Officer | 0 | N/A |
| Blake Salisbury | Senior Vice President | 0 | N/A |
| Min Liu | Chief Commercial Officer | 0 | 1973 |
| Zhengwei Song | Director of IR & Financial Strategy | 0 | N/A |
| Hui Zhou | Chief R&D Officer for Oncology | 0 | N/A |
| Cong Ding | General Counsel | 0 | N/A |
| Fei You | Chief Financial Officer | 0 | 1979 |
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.